ARCTURUS THERAPEUTICS HOLDIN (ARCT) Fundamental Analysis & Valuation

NASDAQ:ARCT • US03969T1097

Current stock price

6.68 USD
-0.32 (-4.57%)
At close:
6.69 USD
+0.01 (+0.15%)
After Hours:

This ARCT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ARCT Profitability Analysis

1.1 Basic Checks

  • ARCT had negative earnings in the past year.
  • ARCT had a negative operating cash flow in the past year.
  • In the past 5 years ARCT reported 4 times negative net income.
  • In the past 5 years ARCT reported 4 times negative operating cash flow.
ARCT Yearly Net Income VS EBIT VS OCF VS FCFARCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -24.26%, ARCT is in the better half of the industry, outperforming 70.91% of the companies in the same industry.
  • ARCT has a Return On Equity of -30.74%. This is in the better half of the industry: ARCT outperforms 74.18% of its industry peers.
Industry RankSector Rank
ROA -24.26%
ROE -30.74%
ROIC N/A
ROA(3y)-18.24%
ROA(5y)-20.9%
ROE(3y)-25%
ROE(5y)-32.17%
ROIC(3y)N/A
ROIC(5y)N/A
ARCT Yearly ROA, ROE, ROICARCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ARCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCT Yearly Profit, Operating, Gross MarginsARCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ARCT Health Analysis

2.1 Basic Checks

  • ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ARCT has more shares outstanding
  • Compared to 5 years ago, ARCT has more shares outstanding
  • ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ARCT Yearly Shares OutstandingARCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ARCT Yearly Total Debt VS Total AssetsARCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -0.29, we must say that ARCT is in the distress zone and has some risk of bankruptcy.
  • ARCT has a Altman-Z score of -0.29. This is comparable to the rest of the industry: ARCT outperforms 57.03% of its industry peers.
  • ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACCN/A
WACC8.92%
ARCT Yearly LT Debt VS Equity VS FCFARCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • ARCT has a Current Ratio of 6.64. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 6.64, ARCT is in the better half of the industry, outperforming 66.47% of the companies in the same industry.
  • ARCT has a Quick Ratio of 6.64. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
  • ARCT has a Quick ratio of 6.64. This is in the better half of the industry: ARCT outperforms 67.05% of its industry peers.
Industry RankSector Rank
Current Ratio 6.64
Quick Ratio 6.64
ARCT Yearly Current Assets VS Current LiabilitesARCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ARCT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.93% over the past year.
  • Looking at the last year, ARCT shows a very negative growth in Revenue. The Revenue has decreased by -46.14% in the last year.
  • Measured over the past years, ARCT shows a very strong growth in Revenue. The Revenue has been growing by 53.90% on average per year.
EPS 1Y (TTM)20.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.21%
Revenue 1Y (TTM)-46.14%
Revenue growth 3Y-26.43%
Revenue growth 5Y53.9%
Sales Q2Q%-68.39%

3.2 Future

  • The Earnings Per Share is expected to grow by 43.17% on average over the next years. This is a very strong growth
  • ARCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.64% yearly.
EPS Next Y-39%
EPS Next 2Y12.54%
EPS Next 3Y41.01%
EPS Next 5Y43.17%
Revenue Next Year-11.09%
Revenue Next 2Y31.06%
Revenue Next 3Y52.41%
Revenue Next 5Y48.64%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ARCT Yearly Revenue VS EstimatesARCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ARCT Yearly EPS VS EstimatesARCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. ARCT Valuation Analysis

4.1 Price/Earnings Ratio

  • ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ARCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCT Price Earnings VS Forward Price EarningsARCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCT Per share dataARCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ARCT's earnings are expected to grow with 41.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.54%
EPS Next 3Y41.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARCT Dividend Analysis

5.1 Amount

  • ARCT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARCT Fundamentals: All Metrics, Ratios and Statistics

ARCTURUS THERAPEUTICS HOLDIN

NASDAQ:ARCT (3/13/2026, 8:10:08 PM)

After market: 6.69 +0.01 (+0.15%)

6.68

-0.32 (-4.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-11
Inst Owners78.42%
Inst Owner Change-6.23%
Ins Owners0.79%
Ins Owner Change0%
Market Cap189.78M
Revenue(TTM)82.03M
Net Income(TTM)-65.78M
Analysts81.11
Price Target35.39 (429.79%)
Short Float %25.03%
Short Ratio13.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.02%
Min EPS beat(2)-41.61%
Max EPS beat(2)41.65%
EPS beat(4)3
Avg EPS beat(4)31.09%
Min EPS beat(4)-41.61%
Max EPS beat(4)62.62%
EPS beat(8)6
Avg EPS beat(8)22.93%
EPS beat(12)9
Avg EPS beat(12)205.31%
EPS beat(16)12
Avg EPS beat(16)178.82%
Revenue beat(2)0
Avg Revenue beat(2)-36.39%
Min Revenue beat(2)-60.07%
Max Revenue beat(2)-12.71%
Revenue beat(4)2
Avg Revenue beat(4)-10.69%
Min Revenue beat(4)-60.07%
Max Revenue beat(4)20.36%
Revenue beat(8)5
Avg Revenue beat(8)19.57%
Revenue beat(12)7
Avg Revenue beat(12)29.24%
Revenue beat(16)10
Avg Revenue beat(16)118.97%
PT rev (1m)0%
PT rev (3m)8.02%
EPS NQ rev (1m)-11.4%
EPS NQ rev (3m)-11.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.43%
Revenue NQ rev (1m)35.74%
Revenue NQ rev (3m)35.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.31
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-3.31
Fwd EYN/A
FCF(TTM)-2.62
FCFYN/A
OCF(TTM)-2.61
OCFYN/A
SpS2.89
BVpS7.53
TBVpS7.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.26%
ROE -30.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.24%
ROA(5y)-20.9%
ROE(3y)-25%
ROE(5y)-32.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.6%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.64
Quick Ratio 6.64
Altman-Z -0.29
F-Score2
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)41.33%
Cap/Depr(5y)183.16%
Cap/Sales(3y)0.82%
Cap/Sales(5y)6.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.21%
EPS Next Y-39%
EPS Next 2Y12.54%
EPS Next 3Y41.01%
EPS Next 5Y43.17%
Revenue 1Y (TTM)-46.14%
Revenue growth 3Y-26.43%
Revenue growth 5Y53.9%
Sales Q2Q%-68.39%
Revenue Next Year-11.09%
Revenue Next 2Y31.06%
Revenue Next 3Y52.41%
Revenue Next 5Y48.64%
EBIT growth 1Y20.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.31%
OCF growth 3YN/A
OCF growth 5YN/A

ARCTURUS THERAPEUTICS HOLDIN / ARCT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ARCTURUS THERAPEUTICS HOLDIN?

ChartMill assigns a fundamental rating of 4 / 10 to ARCT.


What is the valuation status for ARCT stock?

ChartMill assigns a valuation rating of 1 / 10 to ARCTURUS THERAPEUTICS HOLDIN (ARCT). This can be considered as Overvalued.


What is the profitability of ARCT stock?

ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a profitability rating of 1 / 10.